[go: up one dir, main page]

MX2019010981A - Terapias de combinacion para el tratamiento de cancer de mama. - Google Patents

Terapias de combinacion para el tratamiento de cancer de mama.

Info

Publication number
MX2019010981A
MX2019010981A MX2019010981A MX2019010981A MX2019010981A MX 2019010981 A MX2019010981 A MX 2019010981A MX 2019010981 A MX2019010981 A MX 2019010981A MX 2019010981 A MX2019010981 A MX 2019010981A MX 2019010981 A MX2019010981 A MX 2019010981A
Authority
MX
Mexico
Prior art keywords
breast cancer
treatment
combination therapies
inhibitor
combination
Prior art date
Application number
MX2019010981A
Other languages
English (en)
Inventor
Craig D Karr
Manav Korpal
Nathalie Rioux
Peter Gerard Smith
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019010981A publication Critical patent/MX2019010981A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona en la presente una terapia de combinación útil para el tratamiento del cáncer de mama. La combinación comprende un inhibidor de ER-alfa y un inhibidor de CDK A/6.
MX2019010981A 2017-03-16 2018-03-16 Terapias de combinacion para el tratamiento de cancer de mama. MX2019010981A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472345P 2017-03-16 2017-03-16
PCT/US2018/022961 WO2018170447A1 (en) 2017-03-16 2018-03-16 Combination therapies for the treatment of breast cancer

Publications (1)

Publication Number Publication Date
MX2019010981A true MX2019010981A (es) 2020-09-07

Family

ID=61874039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010981A MX2019010981A (es) 2017-03-16 2018-03-16 Terapias de combinacion para el tratamiento de cancer de mama.

Country Status (14)

Country Link
US (1) US11083722B2 (es)
EP (2) EP4218820A3 (es)
JP (1) JP7219224B2 (es)
KR (1) KR102517650B1 (es)
CN (1) CN110636862A (es)
AU (1) AU2018234903B2 (es)
BR (1) BR112019019261A2 (es)
CA (1) CA3056701A1 (es)
IL (1) IL269357B2 (es)
MA (1) MA47776A (es)
MX (1) MX2019010981A (es)
RU (1) RU2764724C2 (es)
SG (1) SG11201908531WA (es)
WO (1) WO2018170447A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266003B (en) * 2016-11-28 2022-08-01 Eisai R&D Man Co Ltd Salts of indazole derivative and crystals thereof
BR112020013915A2 (pt) 2018-01-08 2020-12-01 G1 Therapeutics, Inc. regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
CA3199087A1 (en) * 2020-11-06 2022-05-12 Eisai R&D Management Co., Ltd. Method of treating breast cancer
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
ATE284400T1 (de) 2000-01-18 2004-12-15 Aventis Pharma Inc Ethanolsolvat von (-)-cis-2-(2-chlorphenyl)-5,7- dihydroxy-8- (4r-(3s-hydroxy-1- methyl)piperidinyl)-4h-1-benzopyran-4-on
PT1259507E (pt) 2000-01-18 2004-12-31 Aventis Pharma Inc Forma pseudopolimorfica de (-)-cis-2-(2-clorofenil)-5,7-di-hidroxi-8[4r(3s-hidroxi-1-metil)piperidinil]-4h-benzopiran-4-ona
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
RU2007131101A (ru) 2005-01-21 2009-02-27 Астекс Терапьютикс Лимитед (Gb) Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
JP5475234B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
US7776832B2 (en) 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
WO2008001101A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
JP2009543768A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド 医薬組み合わせ
WO2008007122A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
JP2009544602A (ja) 2006-07-21 2009-12-17 アステックス・セラピューティクス・リミテッド サイクリン依存性キナーゼ阻害剤の医学的使用
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
PT2331547E (pt) 2008-08-22 2014-10-29 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
ES2689177T3 (es) 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP2955183A1 (en) 2010-10-25 2015-12-16 G1 Therapeutics, Inc. Cdk inhibitors
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
RU2015125307A (ru) 2012-11-28 2017-01-10 Новартис Аг Комбинированная терапия
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
KR102318306B1 (ko) 2013-08-14 2021-10-28 노파르티스 아게 암의 치료를 위한 조합 요법
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
WO2016126889A1 (en) 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
IL255189B2 (en) * 2015-04-29 2024-04-01 Radius Pharmaceuticals Inc A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
HRP20211542T1 (hr) * 2015-05-29 2022-01-07 Eisai R&D Management Co., Ltd. Tetrasupstituirani spojevi alkena i njihova uporaba

Also Published As

Publication number Publication date
IL269357A (en) 2019-11-28
EP3595725A1 (en) 2020-01-22
AU2018234903A1 (en) 2019-10-10
MA47776A (fr) 2020-01-22
JP2020510075A (ja) 2020-04-02
JP7219224B2 (ja) 2023-02-07
WO2018170447A1 (en) 2018-09-20
BR112019019261A2 (pt) 2020-06-16
CN110636862A (zh) 2019-12-31
EP4218820A3 (en) 2023-09-20
CA3056701A1 (en) 2018-09-20
KR20190125448A (ko) 2019-11-06
RU2764724C2 (ru) 2022-01-19
IL269357B2 (en) 2024-10-01
KR102517650B1 (ko) 2023-04-05
EP3595725B1 (en) 2023-05-03
IL269357B1 (en) 2024-06-01
SG11201908531WA (en) 2019-10-30
US11083722B2 (en) 2021-08-10
EP4218820A2 (en) 2023-08-02
RU2019132893A3 (es) 2021-06-24
RU2019132893A (ru) 2021-04-16
US20210113537A1 (en) 2021-04-22
AU2018234903B2 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
IL282727B1 (en) Combination therapy comprising a Krasg12c inhibitor and one or more pharmacologically active agents for the treatment of cancers
EP3849549A4 (en) POLYTHERAPY FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2019010981A (es) Terapias de combinacion para el tratamiento de cancer de mama.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
NZ754865A (en) Combination therapy for the treatment of cancer
EA201791736A1 (ru) Комбинированная терапия для лечения рака
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
AU201814587S (en) Ultrasound therapeutic treatment cart
MX2019002115A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
MX2020001727A (es) Terapia de combinacion.
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MY192385A (en) Methods of treating acute kidney injury
EP4086250A3 (en) Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
MX2019013862A (es) Terapia de combinacion.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
IL304245A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment
MX2021001764A (es) Terapia de combinacion.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.